Sinus Disease in Young Children With Cystic Fibrosis
Eligible age
2–8 yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a prospective, observational study examining the impact of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators on chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) in young children with cystic fibrosis (YCwCF). This study involves two groups: children 2-8 years old, inclusive at initial visit, receiving highly effective modulator therapy (HEMT), and a control group of children 2-8 years old, inclusive at initial visit, not receiving HEMT. Outcomes will include sinus magnetic resonance imaging (MRI) scans, olfactory tests, and quality of life surveys obtained over a two-year period.
Sponsor: University of California, Los Angeles
You may qualify if…
- ✓ HEMT Group:
- ✓ Children with documentation of a CF diagnosis
- ✓ Age 2-8 years old at first study visit
- ✓ CFTR mutation consistent with FDA labeled indication of highly effective modulator therapy (ivacaftor or elexacaftor/tezacaftor/ivacaftor)
- ✓ Clinician intent to prescribe ivacaftor or ETI so that enrollment is before start of HEMT
- ✓ Non-HEMT/Control Group:
- ✓ Children with documentation of a CF diagnosis
- ✓ Age 2-8 years at first study visit
You may not qualify if…
- ✕ For Both Groups:
- ✕ Use of an investigational drug within 28 days prior to the first study visit
- ✕ Use of ivacaftor or elexacaftor/tezacaftor/ivacaftor within the 180 days prior to and including the first study visit
- ✕ Use of chronic oral corticosteroids within the 28 days prior to and including the first study visit.
- ✕ Sinus surgery within 180 days prior to the first study visit
Where it's recruiting
Source: ClinicalTrials.gov · NCT06191640 · last updated 2026-09-10